Open access
Open access
Powered by Google Translator Translator

Phase 2 RCT: Psilocybin, a psychedelic compound, shows promise for the treatment of depression in a study with 59 patients

16 Apr, 2021 | 06:17h | UTC

Trial of Psilocybin versus Escitalopram for Depression – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries: Magic mushroom compound performs as well as antidepressant in small study – Imperial College London AND First-of-its-kind study pits psilocybin against a common antidepressan – STAT AND Psilocybin Not Significantly Different from Escitalopram for Depression – NEJM Journal Watch AND Expert reaction to phase 2 trial comparing psilocybin and escitalopram for depression – Science Media Centre

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.